Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renoprotective effects of empagliflozin in diabetic vs non-diabetic kidney transplant recipients
IRCT20130812014333N168Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM), sponsored by Kermanshah University of Medical Sciences. Started May 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20130812014333N168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130812014333N168.